138 related articles for article (PubMed ID: 14998863)
1. Rituximab-CHOP or two-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Todeschini G; Gelio S; Tecchio C
Ann Oncol; 2004 Mar; 15(3):538-9. PubMed ID: 14998863
[No Abstract] [Full Text] [Related]
2. Rituximab-CHOP or 2-weekly CHOP + G-CSF in aggressive lymphoma of the elderly?
Bernardi D; Giacalone A; Spina M; Tirelli U
Ann Oncol; 2004 Aug; 15(8):1298. PubMed ID: 15277275
[No Abstract] [Full Text] [Related]
3. Phase II study of CHOP-GR therapy for advanced-stage follicular lymphoma.
Tomita N; Kodama F; Oshima R; Hashimoto C; Koharazawa H; Takemura S; Yamazaki E; Fujimaki K; Sakai R; Fujita H; Fujisawa S; Kanamori H; Motomura S; Ishigatsubo Y
Leuk Lymphoma; 2006 Jun; 47(6):1041-7. PubMed ID: 16840195
[TBL] [Abstract][Full Text] [Related]
4. Aspects of chemotherapy schedules in young and elderly patients with aggressive lymphoma.
Zwick C; Gleissner B; Pfreundschuh M
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S43-9. PubMed ID: 18284715
[TBL] [Abstract][Full Text] [Related]
5. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; van der Holt B; van Imhoff GW; van der Hem KG; Kramer MH; van Oers MH; Ossenkoppele GJ; Schaafsma MR; Verdonck LF; Verhoef GE; Steijaert MM; Buijt I; Uyl-de Groot CA; van Agthoven M; Mulder AH; Sonneveld P
J Clin Oncol; 2003 Aug; 21(16):3041-50. PubMed ID: 12915593
[TBL] [Abstract][Full Text] [Related]
6. Aggressive lymphoma: improving treatment outcome with rituximab.
Coiffier B; Pfreundschuh M; Stahel R; Vose J; Zinzani PL
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S43-50. PubMed ID: 12710590
[TBL] [Abstract][Full Text] [Related]
7. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
8. Strategies for improving outcomes with 14-day anthracycline-based regimens in patients with aggressive lymphomas.
Broussais-Guillaumot F; Coiffier B
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S50-6. PubMed ID: 18284716
[TBL] [Abstract][Full Text] [Related]
9. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial.
Osby E; Hagberg H; Kvaløy S; Teerenhovi L; Anderson H; Cavallin-Stahl E; Holte H; Myhre J; Pertovaara H; Björkholm M;
Blood; 2003 May; 101(10):3840-8. PubMed ID: 12531794
[TBL] [Abstract][Full Text] [Related]
10. Intravascular lymphoma presenting with cauda equina syndrome: treated with CHOP and rituxan.
Davis TS
Leuk Lymphoma; 2003 May; 44(5):887-8. PubMed ID: 12802932
[No Abstract] [Full Text] [Related]
11. CHOP versus CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Alliot C
J Clin Oncol; 2005 Jul; 23(21):4797-9; author reply 4799-800. PubMed ID: 16034060
[No Abstract] [Full Text] [Related]
12. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
[TBL] [Abstract][Full Text] [Related]
13. A phase III trial of CHOP vs CHOP + rituximab vs CHOP + 1-131 tositumomab for newly diagnosed follicular non-Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2006 Jul; 4(7):536-8. PubMed ID: 17147240
[No Abstract] [Full Text] [Related]
14. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma.
Arcaini L; Orlandi E; Scotti M; Brusamolino E; Passamonti F; Burcheri S; Colombo N; Vanelli L; Sbalzarini G; Lazzarino M
Clin Lymphoma; 2004 Mar; 4(4):250-2. PubMed ID: 15072617
[TBL] [Abstract][Full Text] [Related]
15. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
[TBL] [Abstract][Full Text] [Related]
16. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Coiffier B
Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense CHOP plus rituximab (R-CHOP14) for the treatment of elderly patients with high-risk diffuse large B cell lymphoma: a pilot study.
Rigacci L; Nassi L; Alterini R; Carrai V; Longo G; Bernardi F; Martini V; Bosi A
Acta Haematol; 2006; 115(1-2):22-7. PubMed ID: 16424645
[TBL] [Abstract][Full Text] [Related]
19. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma.
Coiffier B
Tumori; 2002; 88(1 Suppl 1):S26-8. PubMed ID: 11989916
[No Abstract] [Full Text] [Related]
20. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
Bartlett NL; Petroni GR; Parker BA; Wagner ND; Gockerman JP; Omura GA; Canellos GP; Robert M; Johnson JL; Peterson BA
Cancer; 2001 Jul; 92(2):207-17. PubMed ID: 11466671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
